Jérémie Calais, MD, PhD, of University of California, Los Angeles, provides his list of the clinical trials of interest from the SNMMI Annual Meeting, including a systematic review and meta-analysis for dosimetry of Lutetium-177 PSMA-targeted RLTs for prostate cancer, the phase 2 FLEX-MRT study, and an analysis of PSMA PET/CT-guided, metastasis-directed radiotherapy for oligometastatic CRPC.
View his previous comments on General Reactions From the SNMMI 2024 Annual Meeting.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.